Sansure Biotech Inc. achieved a record high in net profit after deducting non-recurring items in 2024, but the gross margin of diagnostic instruments saw a significant decline.
① The company achieved a revenue of 1.458 billion yuan for the year, a year-on-year increase of 44.78%; the net income excluding non-recurring items was 0.202 billion yuan, a significant year-on-year increase of 182.25%; the net income attributable to the parent company was 0.276 billion yuan, a year-on-year decrease of 24.23%; ② Revenue from diagnostic instruments has significantly declined, with a gross margin that is negative, mainly due to intensified market competition and rising costs.
Shenzhen Mindray Bio-Medical Electronics' Q1 revenue decreased by 12.12% year-on-year, and Net income decreased by 16.81% year-on-year | Earnings Reports Insights.
More news is being continuously updated.
Direct coverage of the Star medical instruments industry collective Earnings Conference: Multiple companies are laying out AI medical Business, and key segments in innovation fields may accelerate the development of domestic production.
① Attending companies believe that tariff policies will bring some cost pressures and market challenges to enterprises, but at the same time, it has accelerated the localization process in relevant fields; ② Some attending companies disclosed the latest developments in their Business during the earnings briefing and the planning for related lines by 2025.
Zhejiang Biology's revenue declines in 2024 while losses narrow, the molecular diagnostics Business faces pressure.
① In 2024, Zhijiang Biology's revenue decreased by 34.88% year-on-year, but losses narrowed; ② Revenue from molecular diagnostic instruments fell by 84.01% year-on-year, which significantly impacted the overall performance of the company.
After the unsuccessful privatization of HENLIUS, FOSUN PHARMA took action to increase its Shareholding. Is it continuing to send Bullish signals? | Quick read of the announcement.
① After the privatization failure last year, FOSUN PHARMA continues to signal its bullish outlook on HENLIUS, and today increased its shareholding in HENLIUS; ② HENLIUS had impressive performance last year, and recently has been actively releasing positive news.
Boai NKY Medical: Last year's Net income decreased by about 30% year-on-year, the proportion of Medical Services Business fell below 10% | Interpretations
① The gross margin of the PVP series products is under pressure, and the company's revenue will increase while profits decrease in 2024; ② The Medical Services business now accounts for less than 10% of the company's performance.